Analyst firms · H.C. Wainwright · ZYME

H.C. Wainwright ZYME price target and rating history

Zymeworks Inc. (ZYME) · Health Care

H.C. Wainwright rates Zymeworks Inc. (ZYME) Buy with a $55 price target, as of its latest action on Aug 26, 2026. It has published 5 rating actions on ZYME since August 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a ZYME price target in the last 12 months, the median target is $33. H.C. Wainwright's $55 is 67% above that.

Current rating
Buy
Price target
$55
Median target, all firms
$33
Actions on ZYME
5

H.C. Wainwright price target on ZYME

$88$52$1620222023202420252026
H.C. Wainwright price target on ZYME, each point a stated target, August 2021 to August 2026. Targets before August 2026 (multiplied by 2) are adjusted for a stock split, going by the prior target H.C. Wainwright restated.

Every H.C. Wainwright rating on ZYME

How other firms rate ZYME

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenBuy$34Sep 29, 2026
Wolfe ResearchOutperformSep 17, 2026
H.C. WainwrightBuy$55Aug 26, 2026
Truist SecuritiesBuy$28Jun 9, 2026
Wells FargoOverweight$33Dec 12, 2025
Citizens JMPMkt Outperform$32Dec 3, 2025

Questions about H.C. Wainwright and ZYME

What is H.C. Wainwright's price target for ZYME?
H.C. Wainwright's latest stated price target for Zymeworks Inc. (ZYME) is $55, from its action on Aug 26, 2026.
What is H.C. Wainwright's rating on ZYME?
H.C. Wainwright rates ZYME Buy, a bullish rating, as of Aug 26, 2026.
When did H.C. Wainwright last change its view on ZYME?
On Aug 26, 2026, H.C. Wainwright raises its price target to $55 from $51, keeps Buy.
How does H.C. Wainwright's ZYME target compare with other analysts?
Across 5 firms with a ZYME price target in the last 12 months, the median target is $33. H.C. Wainwright's $55 is 67% above that.

More ZYME rating histories

All H.C. Wainwright ratingsZYME news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.